SESAM-BIOTECH GMBH

Their core work

SESAM-BIOTECH is a private biotechnology SME based in Aachen, Germany, operating at the intersection of metabolic engineering and enzyme technology. Their participation in MSCA Innovative Training Networks indicates they serve as an industrial host for early-stage researchers, providing hands-on bioprocess and biocatalysis environments that complement academic partners in the consortium. Their project involvement spans predictive metabolic pathway design and enzymatic oxygen activation chemistry — suggesting practical capabilities in fermentation, biocatalytic process development, or enzyme-based industrial applications. As an SME in Aachen's densely connected academic-industrial ecosystem, they likely translate research insights into applied biotechnology solutions.

What they specialise in

How they've shifted over time

With only two projects starting within a single year of each other (2016 and 2017), there is no meaningful long-term evolution to trace — this is effectively a snapshot of one period of activity rather than a trajectory. Both engagements fall within the same domain of industrial biotechnology, with PAcMEN leaning toward systems-level metabolic design and OXYTRAIN toward oxidative enzyme chemistry. No keyword data is available to refine this further, so any claimed shift would be speculation rather than evidence.

Their two known engagements suggest a consistent interest in enzyme-driven biotransformation — if they continue in this direction, they are a plausible partner for projects involving biocatalytic process development or green chemistry applications.

How they like to work

SESAM-BIOTECH has participated exclusively as a consortium partner and has never coordinated an H2020 project, which is typical for SMEs joining MSCA training networks to host researchers rather than lead scientific agendas. Despite only two projects, they have engaged with 23 distinct partners across 12 countries — an unusually broad network footprint that suggests active involvement in large, multi-partner consortia rather than small bilateral collaborations. This profile indicates they are comfortable operating within complex international consortia and bring applied industrial context that academic-heavy networks typically seek.

SESAM-BIOTECH has collaborated with 23 unique partners across 12 countries through just two projects, reflecting the broad consortium structure typical of MSCA-ITN networks. Their European reach is genuine, though it is driven by network composition rather than self-directed partnership strategy.

What sets them apart

As an SME in Aachen — home to one of Europe's strongest technical universities, RWTH Aachen — SESAM-BIOTECH occupies a strategically valuable position between frontier academic research and industrial application in biotechnology. Their willingness to host MSCA researchers signals openness to deep academic collaboration, which makes them an attractive partner for research consortia that need credible industrial validation. For a consortium builder, they offer the rare combination of SME agility, genuine biotech specialization, and demonstrated capacity to integrate PhD-level research into an industrial setting.

Highlights from their portfolio

• PAcMEN
  A flagship MSCA training network on predictive metabolic engineering that brought together academic and industrial partners to accelerate rational design of microbial cell factories — a high-impact area for industrial biotech.
• OXYTRAIN
  Focused on enzymatic oxygen activation, a technically demanding and commercially relevant area underpinning green chemistry and pharmaceutical synthesis, with SESAM-BIOTECH as one of the few SME partners.